levofloxacinstarry
starry 时间:2021-01-09 阅读:(
)
RegulatoryStoryGotomarketnewssectionCompanyCathayInternationalHoldingsLdTIDMCTIHeadlineZhejiangStarryPharmaceuticalCo.
,Ltd.
Released07:0016-Nov-2010Number2440W07RNSNumber:2440WCathayInternationalHoldingsLd16November2010CATHAYINTERNATIONALHOLDINGSLIMITEDProposedminorityinvestmentinZhejiangStarryPharmaceuticalCo.
,Ltd.
('Starry')CathayInternationalHoldingsLtd.
(LSE:CTI.
L)('Cathay'orthe'Company'),acompanyinvestingprimarilyinthegrowingpharmaceuticalandhealthcaresectorsinthePeople'sRepublicofChina('PRC'),announcestodaythat:·LansenPharmaceuticalHoldingsLimited(HKE:503.
HK)('Lansen'),theCompany'ssubsidiarylistedonthemainboardoftheHongKongExchange,hasannouncedtodaythatithasagreedthetermsforthepurchaseofa20%equityinterestinStarry('Lansen'sInvestment')fromanindependentthirdpartyforacashconsiderationofapproximatelyUS$24million;and·theCompanyhasagreedthetermsforthepurchaseofa1.
5%equityinterestinStarry(the'Company'sInvestment')fromthesameindependentthirdpartyforacashconsiderationofapproximatelyUS$1.
8million.
DetailsofthetransactionLansen'sInvestmentistobeeffectedpursuanttoanequitytransferagreement(the'LansenAgreement')underwhichLansenInvestments(HongKong)Limited('LSI'),anindirectwhollyownedsubsidiaryofLansen,hasagreedtopurchaseandMr.
LiewYewThoong(the'Vendor'),oneoftheexistingminorityshareholdersofStarry,hasagreedtosell,20%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$24million(RMB160million).
TheCompany'sInvestmentistobeeffectedpursuanttoaseparateequitytransferagreement(the'CathayAgreement')underwhichFullKeenLimited('FKL')anindirectwholly-ownedsubsidiaryoftheCompany,hasagreedtopurchaseandtheVendorhasagreedtosell,1.
5%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$1.
8million(RMB12million).
ZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
1of411/16/20103:03PMInformationonStarryStarryisasino-foreignequityjointventureincorporatedunderthelawsofthePRC.
Itisacompanyspecializingintheproductionofbulkpharmaceuticalsandintermediates.
ThetwocorebulkpharmaceuticalproductsofStarryareiohexolforX-CTnon-ioniccontrastagentsandlevofloxacinforantibiotics.
StarryisthelargestiohexolmanufacturerinthePRCandisexperiencedintheproductionmanagementandqualitycontrolofbulkpharmaceuticals.
SetoutbelowisasummaryoftheauditedfinancialresultsofStarryforthetwoyearsended31December2008and31December2009,whichwerepreparedinaccordancewiththePRCgenerallyacceptedaccountingprinciples:Yearended31December20092008EquivalentEquivalentRMB'000US$'000RMB'000US$'000Profitbeforetaxation57,9748,72532,8604,945Profitaftertaxation57,9748,72532,8604,945Grossassets549,49182,698467,79470,403Netassets199,70730,056139,05320,927ConsiderationTheconsiderationforLansen'sInvestmentisRMB160million(approximatelyUS$24million),whichshallbefundedthroughtheexistinginternalresourcesoftheLansengroup.
TheconsiderationfortheCompany'sInvestmentisRMB12million(approximatelyUS$1.
8million).
TheconsiderationwillbesatisfiedoutoftheCompany'sinternalresources.
Theconsiderationwasagreedafterarm'slengthnegotiationsbetweenLansen,theCompanyandtheVendor,takingintoconsideration,amongstotherthings,(i)thenetassetvalueofStarryasat31December2009;(ii)futureprospectsofthebusinessofStarry;(iii)theprospectsofthepharmaceuticalindustryinthePRCasawhole;and(iv)tradingpriceearningsmultiplesofStarry'smarketcomparablesinthePRC.
TheconsiderationpayablefortheCompany'sInvestmentandLansen'sInvestmentshallbesettledwithin10businessdaysofreceiptoftherelevantgovernmentapprovalinthePRCforthetransferoftheequityinterestsundertherespectiveagreement.
Iftherelevantgovernmentapprovalforthetransferoftheequityinterestsisnotreceivedwithin60daysfromthedateoftheapplicationforapproval(orsuchotherdateastheVendorandLSIorFKL,asthecasemaybe,mayagree)theLansenAgreementandtheCathayAgreementshalllapseandbeofnofurtherforceandeffect.
EffectofthetransactionontheCathaygroupandbenefitsofthetransactionThereasonsforandexpectedbenefitsofLansen'sInvestmentincludethefollowingmatters:·OneofLansen'sstrategiesistoexploreopportunities,throughbusinessalliancesoracquisitions,whichwouldexpanditsproductrangeofrheumaticspecialtydrugs,includingtheupstreambulkpharmaceuticalproductionforrheumaticspecialtydrugs.
TheboardofLansenbelievesthatLansen'sInvestmentprovidesLansenwithopportunitiestoparticipateintheupstreamZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
2of411/16/20103:03PMsupplybusinessinthepharmaceuticalindustryvaluechain.
Lansen'sInvestmentisofstrategicsignificancesinceLansen'sInvestmentwillallowittodevelopexperienceintheproductionmanagementandcontrolofbulkpharmaceuticalsforitsdrugsinthefuture.
·Theimpactonbulkpharmaceuticalsappeartobelesssubstantialthantheimpactondownstreampharmaceuticalproductsundertherecent"DrugPriceControlMeasures"discussionpaperpublishedbythePRCgovernment.
Lansen'sInvestmentwillachieveacertaindegreeofdiversificationofproductconcentrationrisk.
·Lansen'sboardbelievesthatLansen'sInvestmentisconsistentwithLansen'sbusinessobjectiveofestablishingandstrengtheningbusinessallianceswithpharmaceuticalcompanies.
LansenwillbenefitfromStarry'sexperienceinareasincludingrawmaterialsproductiontechnology,GMPcertification,costandqualitycontrol,andenvironmentalprotection.
LansenisnotexpectedtodevotesignificanthumanandmanagementresourcestoStarry'soperations.
·Lansen'sboardconsidersthatthetermsandconditionsoftheLansenAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheLansenAgreementisintheinterestsofLansenanditsshareholdersasawhole.
ForCathay,theCompany'sInvestmentisinlinewiththeintentionstatedintheCompany's2010interimreporttospecializeinthefastgrowingpharmaceutical,healthcareandenvironmentprotectionmarketsandtowidentheinvestmentscopeoftheCathayGrouptoincludepotentialminorityinvestmentpositions.
TheBoardofCathayconsidersthatthetermsandconditionsoftheCathayAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheCathayAgreementisintheinterestsoftheCompanyanditsshareholdersasawhole.
DetailsofkeyindividualsimportanttothebusinessofStarryMr.
HuJinsheng,56,founderandoneofthemajorshareholdersofStarry,hasbeeninthebusinessforthirtyyearsandpossessesextensiveexperienceinoperationalandfinancialmanagementissues.
Mr.
HuJinshengistheGeneralManagerofStarry.
Mr.
HuJian,thesonofMr.
HuJinsheng,isanothermajorshareholderofStarry.
Mr.
HuJianistheDeputyGeneralManagerofStarry.
EnquiriesCathayInternationalHoldingsLimited+85228289289JinyiLee/EricSiuBrunswick+44(0)2074045959JonColesCertainstatementsinthisannouncementareforward-lookingstatements.
ThesestatementsrelatetotheCathayGroup'sfutureprospects,developmentsandbusinessstrategies.
Forward-lookingstatementsareidentifiedbytheiruseoftermsandphrasessuchas"believe","could","envisage","estimate","intend","may","plan","will"orthenegativeofthose,variationsorcomparableexpressions,includingreferencestoassumptions.
Theforward-lookingstatementsinthisannouncementarebasedoncurrentexpectationsandaresubjecttorisksanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromthoseexpressedorimpliedbythosestatements.
Giventheserisksanduncertainties,potentialinvestorsshouldnotplaceanyrelianceonforward-lookingZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
3of411/16/20103:03PMstatements.
Theseforward-lookingstatementsspeakonlyasatthedateofthisannouncement.
NeithertheDirectorsnortheCompanyundertakeanyobligationtoupdateforward-lookingstatementsotherthanasrequiredbytheListingRules,DisclosureandTransparencyRules,applicablelegislationorbytherulesofanyothersecuritiesregulatoryauthority,whetherasaresultofnewinformation,futureeventsorotherwise.
ThisinformationisprovidedbyRNSThecompanynewsservicefromtheLondonStockExchangeENDMSCDMMMMVVRGGZGLondonStockExchangeplcisnotresponsibleforanddoesnotcheckcontentonthisWebsite.
Websiteusersareresponsibleforcheckingcontent.
Anynewsitem(includinganyprospectus)whichisaddressedsolelytothepersonsandcountriesspecifiedthereinshouldnotberelieduponotherthanbysuchpersonsand/oroutsidethespecifiedcountries.
Termsandconditions,includingrestrictionsonuseanddistributionapply.
2009LondonStockExchangeplc.
AllrightsreservedRegulatoryZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
4of411/16/20103:03PM
Dataideas是一家2019年成立的国外VPS主机商,提供基于KVM架构的VPS主机,数据中心在美国得克萨斯州休斯敦,主机分为三个系列:AMD Ryzen系列、Intel Xeon系列、大硬盘系列,同时每个系列又分为共享CPU和独立CPU系列,最低每月1.5美元起。不过需要注意,这家没有主页,你直接访问根域名是空白页的,还好他们的所有套餐支持月付,相对风险较低。下面以Intel Xeon系列共...
前几天还在和做外贸业务的网友聊着有哪些欧洲机房的云服务器、VPS商家值得选择的。其中介绍他选择的还是我们熟悉的Vultr VPS服务商,拥有比较多达到17个数据中心,这不今天在登录VULTR商家的时候看到消息又新增一个新的机房。这算是第18个数据中心,也是欧洲VPS主机,地区是瑞典斯德哥尔摩。如果我们有需要欧洲机房的朋友现在就可以看到开通的机房中有可以选择瑞典机房。目前欧洲已经有五个机房可以选择,...
阿里云香港配置图提速啦是成立于2012年的十分老牌的一个商家这次给大家评测的是 阿里云香港 16核32G 20M 这款产品,单单说价格上就是十分的离谱原价8631元/月的现价只要 999元 而且还有个8折循环优惠。废话不多说直接进入正题。优惠时间 2021年8月20日-2021年9月20日 优惠码 wn789 8折优惠阿里云香港BGP专线 16核32G 10M带宽 优惠购买 399元购买链接阿里云...
starry为你推荐
虚拟主机代理请问虚拟主机的代理和虚拟主机分销有什么区别?分销的主机是不是可以把主机分给多个用户使用?我用的ResellerClub代理!!网站服务器租用公司想建个网站,请问租服务器按年收费是多少钱虚拟空间免费试用目前哪里有免费试用的虚拟主机 或者服务器用啊?网站空间购买企业网站空间购买的网站空间具体需要多大的合适?网站空间价格1M网站空间是多少钱虚拟主机mysql怎么管理虚拟主机上的MYSQL?(高分回报)河南虚拟主机新网的虚拟主机怎么样?虚拟主机测评哪一种虚拟主机比较好用?西安虚拟主机西安云主机/云主机与vps有哪些区别台湾虚拟主机问 美国、香港、台湾虚拟主机哪个好
移动服务器租用 万网域名空间 vps交流 Vultr 抢票工具 天猫双十一抢红包 青果网 一元域名 京东商城0元抢购 网站cdn加速 169邮箱 免费活动 web服务器安全 四核服务器 域名与空间 韩国代理ip 阿里云免费邮箱 湖南idc 阵亡将士纪念日 512内存 更多